NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free PTGX Stock Alerts $31.94 +0.47 (+1.49%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$31.14▼$32.0150-Day Range$24.66▼$31.4752-Week Range$13.72▼$33.34Volume417,429 shsAverage Volume669,231 shsMarket Capitalization$1.87 billionP/E Ratio13.09Dividend YieldN/APrice Target$38.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Protagonist Therapeutics alerts: Email Address Protagonist Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside19.0% Upside$38.00 Price TargetShort InterestBearish6.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.69Based on 14 Articles This WeekInsider TradingSelling Shares$2.55 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom $1.67 to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.45 out of 5 starsMedical Sector729th out of 929 stocksPharmaceutical Preparations Industry341st out of 433 stocks 2.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Protagonist Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.36% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTGX. Previous Next 2.6 News and Social Media Coverage News SentimentProtagonist Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Protagonist Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,553,328.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $1.67 to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is 13.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is 13.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 169.91.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. About Protagonist Therapeutics Stock (NASDAQ:PTGX)Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Read More PTGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTGX Stock News HeadlinesApril 20, 2024 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,234 SharesMay 14 at 4:44 PM | finance.yahoo.comProtagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 CongressMay 13 at 1:50 AM | americanbankingnews.comHC Wainwright Analysts Reduce Earnings Estimates for Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 11, 2024 | americanbankingnews.comProtagonist Therapeutics, Inc. to Post Q1 2025 Earnings of ($0.69) Per Share, HC Wainwright Forecasts (NASDAQ:PTGX)May 10, 2024 | americanbankingnews.comJMP Securities Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $45.00May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Financials and Promising Clinical TrialsMay 8, 2024 | markets.businessinsider.comProtagonist Therapeutics: Strong Buy Rating on Robust Financials and Promising PipelineMay 8, 2024 | investorplace.comPTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | chron.comProtagonist Therapeutics: Q1 Earnings SnapshotMay 7, 2024 | finance.yahoo.comProtagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic CollaborationsApril 29, 2024 | finance.yahoo.comWe Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) SoonApril 26, 2024 | finance.yahoo.comProtagonist Therapeutics, Inc. (PTGX)April 3, 2024 | finance.yahoo.comProtagonist Therapeutics Inc CEO Sells 25,000 SharesApril 1, 2024 | finance.yahoo.comShareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%March 27, 2024 | markets.businessinsider.comProtagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic PartnershipsMarch 18, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with TakedaMarch 15, 2024 | finance.yahoo.comPTGX Apr 2024 15.000 callMarch 15, 2024 | finance.yahoo.comPTGX Apr 2024 30.000 putMarch 12, 2024 | bizjournals.comThe People's Market owner snaps up former Protagonist space in heart of NoDa for barMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113March 11, 2024 | markets.businessinsider.comStrong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial OutlookMarch 3, 2024 | finance.yahoo.comThis Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This YearMarch 2, 2024 | finance.yahoo.comEarnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their EstimatesMarch 1, 2024 | finance.yahoo.comProtagonist Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | finance.yahoo.comWe're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash BurnSee More Headlines Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/16/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTGX CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees112Year FoundedN/APrice Target and Rating Average Stock Price Target$38.00 High Stock Price Target$45.00 Low Stock Price Target$32.00 Potential Upside/Downside+19.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.44 Trailing P/E Ratio13.09 Forward P/E Ratio19.13 P/E GrowthN/ANet Income$-78,960,000.00 Net MarginsN/A Pretax Margin52.53% Return on Equity43.42% Return on Assets39.59% Debt Debt-to-Equity RatioN/A Current Ratio15.72 Quick Ratio15.72 Sales & Book Value Annual Sales$60 million Price / Sales31.22 Cash FlowN/A Price / Cash FlowN/A Book Value$9.56 per share Price / Book3.34Miscellaneous Outstanding Shares58,650,000Free Float55,719,000Market Cap$1.87 billion OptionableOptionable Beta2.09 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Dinesh V. Patel Ph.D. (Age 67)CEO, President, Secretary & Director Comp: $883.46kDr. Suneel K. Gupta Ph.D. (Age 65)Chief Development Officer Comp: $640.89kDr. Mark Smythe Ph.D. (Age 59)Founder & VP Technology Mr. Asif Ali (Age 50)Executive VP & Chief Financial Officer Mr. Mohammad Masjedizadeh Ph.D.Executive VP & Chief Technical OfficerMr. Matthew M. Gosling (Age 53)Executive VP & General Counsel Ms. Carena SpiveyHead of HR & Senior VP of Human ResourcesDr. Ashok Bhandari Ph.D. (Age 60)Executive VP & Chief Drug Discovery and Preclinical Development Officer Mr. Carter J. King (Age 53)Executive Vice President of Business Development Ms. Abha BommireddiExecutive Vice President of Portfolio & Program ManagementMore ExecutivesKey CompetitorsFive Prime TherapeuticsNASDAQ:FPRXHarmony BiosciencesNASDAQ:HRMYSchrödingerNASDAQ:SDGRStructure TherapeuticsNASDAQ:GPCRArdelyxNASDAQ:ARDXView All CompetitorsInsiders & InstitutionsBVF Inc. ILSold 1,988,858 shares on 5/16/2024Ownership: 6.404%Kynam Capital Management LPSold 860,633 shares on 5/16/2024Ownership: 1.951%Kennedy Capital Management LLCSold 6,722 shares on 5/16/2024Ownership: 0.508%Silvercrest Asset Management Group LLCBought 8,247 shares on 5/16/2024Ownership: 0.322%Caxton Associates LPBought 16,047 shares on 5/16/2024Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions PTGX Stock Analysis - Frequently Asked Questions Should I buy or sell Protagonist Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks. What is Protagonist Therapeutics' stock price target for 2024? 4 brokerages have issued 12-month price targets for Protagonist Therapeutics' stock. Their PTGX share price targets range from $32.00 to $45.00. On average, they anticipate the company's share price to reach $38.00 in the next year. This suggests a possible upside of 19.0% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts. How have PTGX shares performed in 2024? Protagonist Therapeutics' stock was trading at $22.93 at the beginning of the year. Since then, PTGX shares have increased by 39.3% and is now trading at $31.94. View the best growth stocks for 2024 here. When is Protagonist Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our PTGX earnings forecast. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its quarterly earnings data on Tuesday, February, 27th. The company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.39. The company earned $60 million during the quarter, compared to the consensus estimate of $60 million. What ETFs hold Protagonist Therapeutics' stock? ETFs with the largest weight of Protagonist Therapeutics (NASDAQ:PTGX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE). When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (6.40%), Vanguard Group Inc. (5.44%), Kynam Capital Management LP (1.95%), Price T Rowe Associates Inc. MD (1.40%), Kennedy Capital Management LLC (0.51%) and Silvercrest Asset Management Group LLC (0.32%). Insiders that own company stock include Asif Ali, David Y Liu, Dinesh V Ph D Patel, Suneel Gupta and William D Waddill. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTGX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
